Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.72 |
| ▸ | TP53 | P04637 | 4/20 | 0.72 |
| ▸ | MMP1 | P03956 | 4/20 | 0.72 |
| ▸ | MMP2 | P08253 | 4/20 | 0.72 |
| ▸ | MMP9 | P14780 | 4/20 | 0.72 |
| ▸ | THRB | P10828 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 5/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | THPO | P40225 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3447730 | 1.00 | MAPT (0.72) | MAPTSMN1; SMN2TP53MMP1MMP2 | |
| SCHEMBL17693073 | 0.90 | MAPT (0.88) | MAPTSMN1; SMN2TP53MMP1MMP2 | |
| 4-Methoxy-Cinnamanilide SCHEMBL14375152 | 0.85 | MMP1 (0.89) | MAPTSMN1; SMN2TP53MMP1MMP2 | |
| SCHEMBL14960821 | 0.84 | MAPT (0.72) | MAPTSMN1; SMN2TP53MMP1MMP2 | |
| SCHEMBL21625686 | 0.83 | MAPT (1.00) | MAPTSMN1; SMN2TP53MMP1MMP2 | |
| N-(4-Methoxyphenyl)Cinnamamide SCHEMBL4131114 | 0.82 | MMP1 (1.00) | MAPTSMN1; SMN2TP53MMP1MMP2 | |
| N-(4-Methoxyphenyl)Cinnamamide SCHEMBL4131112 | 0.82 | MMP1 (1.00) | MAPTSMN1; SMN2TP53MMP1MMP2 | |
| N-(4-Methoxyphenyl)Cinnamamide SCHEMBL9094893 | 0.82 | MMP1 (1.00) | MAPTSMN1; SMN2TP53MMP1MMP2 | |
| SCHEMBL8751515 | 0.82 | MAPT (0.77) | MAPTSMN1; SMN2TP53MMP1MMP2 | |
| SCHEMBL8751492 | 0.82 | MAPT (0.77) | MAPTSMN1; SMN2TP53MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907109-B2 | Methods and systems for treating cell proliferation disorders with psoralen derivatives | IMMUNOLIGHT, LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-8791275-B2 | Methods and systems for treating cell proliferation disorders with psoralen derivatives | DUKE UNIVERSITY (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130129757-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | IMMUNOLIGHT, LLC (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131429-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | lmmunolight, LLC (US) | 2013-05-23 | — | — | US | disclosed |
| US-8383836-B2 | Methods and systems for treating cell proliferation disorders with psoralen derivatives | DUKE UNIVERSITY (US) | 2013-02-26 | — | — | US | disclosed |
| US-20100266621-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | DUKE UNIVERSITY (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266621-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | CDK20, NFATC1, CDK10 | MAPT 4295/4885SMN1; SMN2 2128/4885TP53 408/4885 |
| US-20130131429-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | CDK20, NFATC1, CDK10 | MAPT 4295/4885SMN1; SMN2 2128/4885TP53 408/4885 |
| US-20130129757-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | CDK20, NFATC1, CDK10 | MAPT 4295/4885SMN1; SMN2 2128/4885TP53 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.